Britain's NHS approved capivasertib, a drug slowing incurable HR-positive HER2-negative breast cancer. Over 1,000 women may benefit from this twice-daily pill, delaying disease progression and chemotherapy. Clinical trials showed a 4.2-month improvement compared to a placebo. This landmark approval follows decades of research and offers hope to patients with limited treatment options.
